Suchergebnisse - "Schmid, Peter"

PubPharm (633)

101

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. Reply

enthalten in: The New England journal of medicine | 2019

von Schmid, P. | Chui, S. | Emens, L.

CommentOn: N Engl J Med. 2019 Mar 7;380(10):985-986. - PMID 30855754

102

Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer : A Phase 1 Study

enthalten in: JAMA oncology | 2019

von Emens, L. | Cruz, C. | Eder, J. | +16

103

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

enthalten in: The New England journal of medicine | 2018

von Schmid, P. | Adams, S. | Rugo, H. | +16

CommentIn: Cancer Discov. 2019 Jan;9(1):OF5. - PMID 30464002

104

FIR : Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLC

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2018

von Spigel, D. | Chaft, J. | Gettinger, S. | +11

105

Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1)

enthalten in: Proceedings of the National Academy of Sciences of the United States of America | 2018

von Kowanetz, M. | Zou, W. | Gettinger, S. | +27

106

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC) : an open-label, single-arm, phase 2 study

enthalten in: The Lancet. Oncology | 2018

von Garassino, M. | Cho, B. | Kim, J. | +116

CommentIn: Lancet Oncol. 2018 Apr;19(4):438-439. - PMID 29545096

107

Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2018

von Traina, T. | Miller, K. | Yardley, D. | +17

CommentIn: Cancer Discov. 2018 Apr;8(4):OF8. - PMID 29439153

108

PHLDA1 Mediates Drug Resistance in Receptor Tyrosine Kinase-Driven Cancer

enthalten in: Cell reports | 2018

von Fearon, A. | Carter, E. | Clayton, N. | +16

109

The emerging world of breast cancer immunotherapy

enthalten in: Breast (Edinburgh, Scotland) | 2018

von Nathan, M. | Schmid, P.

110

Persistent organic pollutants in red- and white-blooded High-Antarctic notothenioid fish from the remote Weddell Sea

enthalten in: Chemosphere | 2018

von Strobel, A. | Schmid, P. | Burkhardt-Holm, P. | +2